Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

Summary

This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.

Eligibility

Inclusion Criteria:

* Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).
* Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.
* Cohort B: Patients newly diagnosed from October 2025 onward.
* Availability of basic diagnostic and treatment records .

Exclusion Criteria:

* Indeterminate diagnosis or missing pathology report.
* Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.
* Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.

Conditions2

Browse More Trials